Page 22 - BH-1-2
P. 22
Brain & Heart Pemafibrate in patients with dyslipidemia
Figure 4. Significant decrease in low-protein lipoprotein within the placebo group.
Figure 5. No difference in total cholesterol between the groups.
Figure 6. Significant reduction in serum triglycerides following treatment with pemafibrate at 0.4 mg/day.
Figure 7. Significantly lower non-high-density lipoprotein levels following treatment with pemafibrate at 0.4 mg/day.
Figure 8. Significantly lower low-density lipoprotein levels in the placebo group versus treatment with pemafibrate at 0.4 mg/day.
Volume 1 Issue 2 (2023) 6 https://doi.org/10.36922/bh.1629
